Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHIR-02: 89Zr-trastuzumab PET/CT for ADC Sequencing in Advanced HER2+ Breast Cancer
NCT06595563Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Institut Jules Bordet. Started Jun 2026; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06595563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06595563.